公开(公告)号：US09290452B2

公开(公告)日：2016-03-22

申请号：US14415875

申请日：2013-08-05

Applicant: BASF SE

Inventor： Andreas Hafner ,  Fritz Blatter ,  Eva Roedel ,  Martin Szelagiewicz ,  Tiziana Chiodo ,  Tobias Hintermann ,  Beate Salvador ,  Marcus Vossen

IPC: C07D213/81 ,  C07D249/08

CPC classification number: C07D213/81 ,  C07B2200/13 ,  C07D249/08

Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN: Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.

Abstract translation: 本发明涉及包含式（1）化合物（4- [3,5-双（2-羟基苯基）-1H-1,2,4-三唑-1-基）的多组分结晶体（共晶体） ]苯甲酸; INN：Deferasirox）式（1）和式（2）化合物（异烟酰胺;吡啶-4-甲酰胺）式（2），以及其获得方法。

公开(公告)号：US20150246901A1

公开(公告)日：2015-09-03

申请号：US14433147

申请日：2013-10-16

Applicant: BASF SE

Inventor： Tiziana Chiodo ,  Andreas Hafner ,  Tobias Hintermann ,  Beate Salvador ,  Martin Szelagiewicz ,  Fritz Blatter ,  Eva Roedel ,  Marcus Vossen

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

Abstract translation: 本发明涉及包含尼罗替尼和羧酸，羧酸酯，羧酸酰胺或磺酸作为共晶体形成剂的结晶材料以及包含所述材料的药物组合物。 本发明还涉及制备所述结晶材料的方法以及使用所述结晶材料治疗其中酪氨酸激酶抑制是有益的疾病状况的方法。

公开(公告)号：US20150087657A1

公开(公告)日：2015-03-26

申请号：US14360799

申请日：2012-12-03

Applicant: BASF SE

Inventor： Andreas Hafner ,  Tobias Hintermann ,  Fritz Blatter ,  Eva Roedel

IPC: A61K31/506 ,  A61K31/194

CPC classification number: A61K31/506 ,  A61K31/194 ,  C07D403/10 ,  A61K2300/00

Abstract: A novel solid form of Voriconazole comprises the active ingredient (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol and fumaric acid. The solid composition comprising the two components shows improved properties such as water solubility, crystallization behavior and stability.

Abstract translation: 伏立康唑的新型固体形式包括活性成分（2R，3S）-2-（2,4-二氟苯基）-3-（5-氟嘧啶-4-基）-1-（1H-1,2,4-三唑 -1-基）丁-2-醇和富马酸。 包含两种组分的固体组合物显示出改进的性能，例如水溶性，结晶行为和稳定性。